Insilico Medicine, Inc Announces Research Collaboration

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Insilico Medicine, Inc Announces Research Collaboration with Champions Oncology, Inc

BALTIMORE, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused on research in aging and age related diseases announced a research collaboration with the international leader in personalized medicine of cancer, Champions Oncology, Inc.

"There are many companies utilizing advances in genomics for personalized medicine, but Champions Oncology's TumorGraft technology is unique in a way that it can validate the chemotherapy regimen experimentally generating vast amounts of valuable data. Our bioinformatic analysis showed that molecular signatures of patient tumor grafts in mice are very similar to signatures of cancer in patients before and after treatment. We established this research collaboration to further validate these preliminary findings," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

Champions TumorGrafts are a personalized approach used to guide physician treatment decisions for cancer patients. A piece of the patient's living tumor is removed during surgery or biopsy and engrafted in immune-deficient mice. After the TumorGraft grows, still closely resembling the patient's tumor, Champions Oncology tests drug treatments in the TumorGraft and measures the response. TumorGraft has demonstrated high rates of predictability using multiple therapies, including single-agent and combination, chemotherapy regimens and targeted biological drugs.

Every TumorGraft is preserved as a living sample for future patient use. These banked TumorGrafts can be re-grown and tested in the event of cancer progression or recurrence. In oncology drug development, TumorGraft models are utilized extensively by pharmaceutical and biotechnology organizations to predict the clinical effectiveness of their compounds in targeted patient populations.

"Our preliminary collaboration with Insilico Medicine showed some exciting results that may be of interest to both the academic and industry communities," said KerenPaz, chief Scientific Officer at Champions Oncology.

In the scope of this research collaboration Insilico Medicine will analyze a portion of Champions Oncology gene expression data sets from tumor grafts before and after treatment with chemotherapy drugs and compare the signaling pathway activation state(SPAS) changes with the SPAS changes in human patients.

"Champions' Tumorgraft technology stems from many years of breakthrough science generated in the most credible, productive and innovative cancer research laboratories headed by Dr. David Sidransky, who's work we greatly admire. We believe that the TumorGraft technology has broad applications in drug discovery and drug repurposing in aging and age-related diseases that were previously overlooked. This research collaboration may pave the way for a comprehensive drug discovery and development pipeline, where drugs and drug candidates may be selected and prioritized using in silico approaches and tested in human tissues engrafted into Champions Oncology mice or other animal models," said Qingsong Zhu, PhD, Chief Operating Officer, Insilico Medicine, Inc.

About Insilico Medicine

Insilico Medicine is a Baltimore-based company utilizing advances in advances in genomics and big data analysis for in silico drug discovery and drug repurposing for aging and age-related. The company is utilizing the GeroScope™ and OncoFinder™ packages for aging and cancer research. Through internal expertise and extensive collaborations with brilliant scientists, institutions, and highly credible pharmaceutical companies, Insilico Medicine seeks to discover new drugs and drug combinations for personalized preventative medicine. For more information on Insilico Medicine, Inc. please visit http://www.insilicomedicine.com .

About Champions Oncology

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit http://www.championsoncology.com .

Please contact:
Michael Petr
Market Research Associate
michael(dot)petr(at)insilicomedicine(dot)com

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/11/prweb12300021.htm

InSilico Medicine, Inc. Qingsong Zhu, PhD +1 4434517212

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 0

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 202

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 49

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 24

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 28

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 89

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 83

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 42

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 38

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring High ROIC Tech Stocks: Key Insights and Analysis

Updated Category News Views 284

Understanding ROIC in Tech Stocks Return on Invested Capital (ROIC) is a vital indicator when evaluating a company's financial performance and investment potential. It reflects how efficiently a firm uses the capital invested by shareholders to generate profits. High ROIC values signal that a company is not only effective in utilizing its resources but may also be poised...

Continue Reading
Join AVITA Medical's Upcoming Investor Webinar Event

Updated Category News Views 141

AVITA Medical Plans Informative Investor Webinar AVITA Medical, Inc. (NASDAQ: RCEL), known for its innovative approaches to acute wound care, is gearing up to host an insightful investor webinar. The CEO, Jim Corbett, alongside CFO, David O'Toole, will lead this engaging session and discuss the latest financial results and strategic business developments. Details of the...

Continue Reading
Labour Government's Budget Aims to Restore Market Stability

Updated Category News Views 138

Introduction to the New Labour Budget The newly formed Labour government has introduced its first budget, aiming to restore confidence in the UK markets. With a focus on substantial tax increases and strategic spending control, this budget seeks to avoid the destabilizing impact seen during Liz Truss's tenure. The measures announced are designed to bolster the economy...

Continue Reading
Beacon Energy to Host Annual General Meeting This December

Updated Category News Views 166

Beacon Energy's Annual General Meeting Update Beacon Energy plc (AIM: BCE, NYSE: BCE) is an oil and gas company dedicated to developing its onshore assets in Germany. Recently, the company confirmed that it is set to hold its Annual General Meeting (AGM) on December 18, 2024. This significant event will be hosted at 55 Athol Street, Douglas, Isle of Man, providing a prime...

Continue Reading
Okeanis Eco Tankers: Key Insights Ahead of Earnings Call

Updated Category News Views 130

Anticipating Okeanis Eco Tankers' Upcoming Earnings Okeanis Eco Tankers (NYSE:ECO) is preparing to release its latest quarterly earnings report soon. Investors and analysts are keenly focused on what this announcement will bring, particularly in terms of earnings expectations and guidance for upcoming quarters. Expected Earnings Report Industry analysts anticipate that...

Continue Reading